Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal ISM (Intisari Sains Medis) : Jurnal Kedokteran
Ni Nyoman Widyasari
Radiology Residency Program, Faculty of Medicine, Universitas Udayana-Sanglah General Hospital Denpasar, Bali, Indonesia
Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Transarterial chemoembolization (TACE) in hepatocellular carcinoma BCLC B patients: case series Ni Nyoman Widyasari; Firman Parulian Sitanggang; Putu Patriawan; Dewa Gede Mahiswara
Intisari Sains Medis Vol. 12 No. 1 (2021): (Available online : 1 April 2021)
Publisher : DiscoverSys Inc.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (958.817 KB) | DOI: 10.15562/ism.v12i1.916

Abstract

Introduction: Hepatocellular carcinoma (HCC) is the fifth leading cause of death for men and the seventh for women worldwide, HCC is one out of 10 most cancers in Indonesia. HCC grows in the background of chronic liver disease and often associated with hepatitis virus infection such as hepatitis B virus (HBV) and hepatitis C virus (HCV).  Transarterial chemoembolization (TACE) is a minimally invasive procedure performed by interventional radiologist as the treatment of choice for intermediate stage HCC.Case report: Here in we report a 62 and 59 years old female with hepatocellular carcinoma Barcelona clinic liver cancer (BCLC) B who were treated with TACE using 50 mg doxorubicin mixed with Iopamiro and lipiodol. Both were patients with history of HBV infection. After 5 weeks of TACE, triphase abdominal CT-Scan was done to evaluate tumour progression, however one patient was loss to follow up.  Evaluation of one patient was done and revealed more than 30% decrease  solid viable tumour with increase of necrotic area.  Expansion of necrotic area is one of the HCC treatment response criteria, while decrease tumour enhancement explains the viability of the tumour itself.Conclusion: TACE is the therapy of choice for patient with HCC BCLC B, which can give enlargement of necrotic area and decrease tumour viability.  
Co-Authors Dewa Gede Mahiswara Suadiatmika Firman Parulian Sitanggang Patriawan, Putu